1
|
Rakers V, Wang J, Kou D. Accelerated Predictive Stability Study of a Pediatric Drug Product for a Supplemental New Drug Application. AAPS PharmSciTech 2024; 25:128. [PMID: 38844721 DOI: 10.1208/s12249-024-02848-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 05/21/2024] [Indexed: 09/05/2024] Open
Abstract
In this paper, we report two Accelerated Stability Assessment Program (ASAP) studies for a pediatric drug product. Whereas the first study using a generic design failed to establish a predictive model, the second one was successful after troubleshooting the first study and customizing the study conditions. This work highlighted important lessons learned from designing an ASAP study for formulations containing excipients that could undergo phase change at high humidity levels. The stability predictions by the second ASAP model were consistent with available long-term stability data of the drug product under various storage conditions in two different packaging configurations. The ASAP model was part of the justifications accepted by the health authority to submit a stability package with reduced long-term stability data from the primary stability batches for a Supplemental New Drug Application (sNDA).
Collapse
Affiliation(s)
- Viktoria Rakers
- Small Molecule Analytical Research and Development, F. Hoffmann-La Roche AG, Basel, Switzerland
| | - Jin Wang
- Pharma Technical Regulatory, Genentech Inc., South San Francisco, California, USA
| | - Dawen Kou
- Synthetic Molecule Pharmaceutical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
| |
Collapse
|
2
|
McCaig L, Nowak S, Abbott A, Carhart J, McMahon ME, Debie E, Li H, Maina F, Ji AJ, Fu M, Wu Y, Lennard A, Mazzeo T, Wolfe C, Timpano R, Babayan Y, Gruenig L. Science- and Risk-Based Stability Strategies to Support Product Lifecycle Changes. AAPS J 2024; 26:34. [PMID: 38485849 DOI: 10.1208/s12248-024-00903-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Accepted: 02/27/2024] [Indexed: 03/19/2024] Open
Abstract
ICH Q12 asserts that science- and risk-based approaches are applicable to stability studies supporting Chemistry, Manufacturing and Controls (CMC) post-approval changes (PAC) to enable more timely implementation; however, no guidance or specific examples are provided to demonstrate how prior knowledge of the product can inform the risk assessment for the proposed change(s). Ten diverse case studies are presented in this manuscript to demonstrate how science- and risk-based stability strategies were used to support drug substance and product CMC PAC and lifecycle management activities. The accumulated stability knowledge held by original manufacturers of marketed products is substantial, and different elements of this knowledge base were used to assess the risks and impact of the proposed changes for confident change management. This paper provides ways to leverage science- and risk-based stability strategies as part of the post-approval change-management risk-mitigation strategy, which may enable a reduced stability data commitment and/or a reduced reporting category for change implementation.
Collapse
Affiliation(s)
- Lori McCaig
- Pfizer Inc, 21823 30Th Drive SE, Bothell, Washington, 98021, USA
| | - Steven Nowak
- AbbVie, 1 N Waukegan Rd. Bldg. AP50; Dept PA71, North Chicago, Illinois, 60064, USA.
| | - Alexander Abbott
- Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA, UK
| | - Jenny Carhart
- Takeda Development Center Americas, Inc. 95 Hayden Ave, Lexington, Massachusetts, 02421, USA
| | - Megan E McMahon
- Pfizer Inc, Eastern Point Road, Groton, Connecticut, 06340, USA
| | - Elke Debie
- Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium
| | - Hanlin Li
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts, 02210, USA
| | - Francis Maina
- AbbVie, 1401 Sheridan Road, North Chicago, Illinois, 60064, USA
| | - Andrea J Ji
- Genentech Inc, 1 DNA Way, South San Francisco, California, 94080, USA
| | - Mingkun Fu
- Sumitomo Pharma America, 84 Waterford Drive, Marlborough, Massachusetts, 01752, USA
| | - Yan Wu
- Merck & Co, 2000 Galloping Hill Road, Kenilworth, New Jersey, 07033, USA
| | - Andrew Lennard
- Amgen Ltd, 4, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK
| | - Tony Mazzeo
- Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey, 08903, USA
| | - Chad Wolfe
- Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, USA
| | - Robert Timpano
- Pfizer Inc, Eastern Point Road, Groton, Connecticut, 06340, USA
| | - Yelizaveta Babayan
- Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, USA
| | - Lars Gruenig
- CSL Behring, CSL Behring AG, Wankdorfstrasse 10, CH-3014, Bern, Switzerland
| |
Collapse
|
3
|
Tafech B, Mohabatpour F, Hedtrich S. Surface modification of lipid nanoparticles for gene therapy. J Gene Med 2024; 26:e3642. [PMID: 38043928 DOI: 10.1002/jgm.3642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 10/30/2023] [Accepted: 11/05/2023] [Indexed: 12/05/2023] Open
Abstract
Gene therapies have the potential to target and effectively treat a variety of diseases including cancer as well as genetic, neurological, and autoimmune disorders. Although we have made significant advances in identifying non-viral strategies to deliver genetic cargo, certain limitations remain. In general, gene delivery is challenging for several reasons including the instabilities of nucleic acids to enzymatic and chemical degradation and the presence of restrictive biological barriers such as cell, endosomal and nuclear membranes. The emergence of lipid nanoparticles (LNPs) helped overcome many of these challenges. Despite its success, further optimization is required for LNPs to yield efficient gene delivery to extrahepatic tissues, as LNPs favor accumulation in the liver after systemic administration. In this mini-review, we provide an overview of current preclinical approaches in that LNP surface modification was leveraged for cell and tissue targeting by conjugating aptamers, antibodies, and peptides among others. In addition to their cell uptake and efficiency-enhancing effects, we outline the (dis-)advantages of the different targeting moieties and commonly used conjugation strategies.
Collapse
Affiliation(s)
- Belal Tafech
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Fatemeh Mohabatpour
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Sarah Hedtrich
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
- Center of Biological Design, Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Berlin, Germany
- Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| |
Collapse
|
4
|
González-González O, Ramirez IO, Ramirez BI, O’Connell P, Ballesteros MP, Torrado JJ, Serrano DR. Drug Stability: ICH versus Accelerated Predictive Stability Studies. Pharmaceutics 2022; 14:2324. [PMID: 36365143 PMCID: PMC9693625 DOI: 10.3390/pharmaceutics14112324] [Citation(s) in RCA: 33] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Revised: 10/23/2022] [Accepted: 10/25/2022] [Indexed: 07/30/2023] Open
Abstract
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), along with the World Health Organization (WHO), has provided a set of guidelines (ICH Q1A-E, Q3A-B, Q5C, Q6A-B) intended to unify the standards for the European Union, Japan, and the United States to facilitate the mutual acceptance of stability data that are sufficient for registration by the regulatory authorities in these jurisdictions. Overall, ICH stability studies involve a drug substance tested under storage conditions and assess its thermal stability and sensitivity to moisture. The long-term testing should be performed over a minimum of 12 months at 25 °C ± 2 °C/60% RH ± 5% RH or at 30 °C ± 2 °C/65% RH ± 5% RH. The intermediate and accelerated testing should cover a minimum of 6 months at 30 °C ± 2 °C/65% RH ± 5% RH (which is not necessary if this condition was utilized as a long-term one) and 40 °C ± 2 °C/75% RH ± 5% RH, respectively. Hence, the ICH stability testing for industrially fabricated medicines is rigorous and tedious and involves a long period of time to obtain preclinical stability data. For this reason, Accelerated Predictive Stability (APS) studies, carried out over a 3-4-week period and combining extreme temperatures and RH conditions (40-90 °C)/10-90% RH, have emerged as novel approaches to predict the long-term stability of pharmaceutical products in a more efficient and less time-consuming manner. In this work, the conventional ICH stability studies versus the APS approach will be reviewed, highlighting the advantages and disadvantages of both strategies. Furthermore, a comparison of the stability requirements for the commercialization of industrially fabricated medicines versus extemporaneous compounding formulations will be discussed.
Collapse
Affiliation(s)
- Olga González-González
- Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal, s/n, 28040 Madrid, Spain
| | - Irving O. Ramirez
- Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal, s/n, 28040 Madrid, Spain
| | - Bianca I. Ramirez
- Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal, s/n, 28040 Madrid, Spain
| | - Peter O’Connell
- Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal, s/n, 28040 Madrid, Spain
| | - Maria Paloma Ballesteros
- Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal, s/n, 28040 Madrid, Spain
- Instituto Universitario de Farmacia Industrial (IUFI), Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal, s/n, 28040 Madrid, Spain
| | - Juan José Torrado
- Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal, s/n, 28040 Madrid, Spain
- Instituto Universitario de Farmacia Industrial (IUFI), Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal, s/n, 28040 Madrid, Spain
| | - Dolores R. Serrano
- Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal, s/n, 28040 Madrid, Spain
| |
Collapse
|
5
|
Long-Term Stability Prediction for Developability Assessment of Biopharmaceutics Using Advanced Kinetic Modeling. Pharmaceutics 2022; 14:pharmaceutics14020375. [PMID: 35214107 PMCID: PMC8880208 DOI: 10.3390/pharmaceutics14020375] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 01/23/2022] [Accepted: 02/04/2022] [Indexed: 12/04/2022] Open
Abstract
A crucial aspect of pharmaceutical development is the demonstration of long-term stability of the drug product. Biopharmaceuticals, such as proteins or peptides in liquid formulation, are typically administered via parental routes and should be stable over the shelf life, which generally includes a storing period (e.g., two years at 5 °C) and optionally an in-use period (e.g., 28 days at 30 °C). Herein, we present a case study where chemical degradation of SAR441255, a therapeutic peptide, in different formulations in combination with primary packaging materials was analyzed under accelerated conditions to derive long-term stability predictions for the recommended storing conditions (two years at 5 °C plus 28 days at 30 °C) using advanced kinetic modeling. These predictions served as a crucial decision parameter for the entry into clinical development. Comparison with analytical data measured under long-term conditions during the subsequent development phase demonstrated a high prediction accuracy. These predictions provided stability insights within weeks that would otherwise take years using measurements under long-term stability conditions only. To our knowledge, such in silico studies on stability predictions of a therapeutic peptide using accelerated chemical degradation data and advanced kinetic modeling with comparisons to subsequently measured real-life long-term stability data have not been described in literature before.
Collapse
|
6
|
Lin X, Choi PM, Thompson J, Reeks T, Verhagen R, Tscharke BJ, O'Malley E, Shimko KM, Guo X, Thomas KV, O'Brien JW. Systematic Evaluation of the In-Sample Stability of Selected Pharmaceuticals, Illicit Drugs, and Their Metabolites in Wastewater. ENVIRONMENTAL SCIENCE & TECHNOLOGY 2021; 55:7418-7429. [PMID: 34014086 DOI: 10.1021/acs.est.1c00396] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The in-sample stability of selected pharmaceuticals, illicit drugs, and their metabolites in wastewater was assessed under six different conditions-untreated, addition of hydrochloric acid or sodium metabisulfite solution, combined with or without sterile filtration, and at four representative temperatures, at 35 °C for up to 28 days, 22 °C for 56 days, and 4 °C and -20 °C for 196 days, or freeze/thaw cycles for 24 weeks. Paracetamol, 6-monoacetylmorphine, morphine, and cocaine were poorly stable in untreated wastewater-e.g., with 50% transformation within 1.2-8.1 days at 22 °C, and acidification reduced their in-sample transformations. Acesulfame, carbamazepine, cotinine, methamphetamine, 3,4-methylenedioxy-methamphetamine (MDMA), ketamine, norfentanyl, 3,4-methylenedioxy-N-ethylamphetamine (MDEA), and norbuprenorphine were highly or moderately stable over the observed period, even in untreated wastewater. Fitting of pseudo-first-order kinetics and the Arrhenius equation was used to develop a multistage transformation estimation model combined with an interactive tool to evaluate possible transformation scenarios of selected biomarkers for the processes from sampling to preanalysis. However, as the wastewater composition can vary between sites and over time, the variability of in-sample stability requires further exploration.
Collapse
Affiliation(s)
- Xialu Lin
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China
| | - Phil M Choi
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia
| | - Jack Thompson
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia
| | - Timothy Reeks
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia
| | - Rory Verhagen
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia
| | - Benjamin J Tscharke
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia
| | - Elissa O'Malley
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia
| | - Katja M Shimko
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia
| | - Xiong Guo
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China
| | - Kevin V Thomas
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia
| | - Jake W O'Brien
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia
| |
Collapse
|
7
|
Cho E, Mayhugh BM, Srinivasan JM, Sacha GA, Nail SL, Topp EM. Stability of antibody drug conjugate formulations evaluated using solid-state hydrogen-deuterium exchange mass spectrometry. J Pharm Sci 2021; 110:2379-2385. [PMID: 33711346 DOI: 10.1016/j.xphs.2021.03.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Antibody drug conjugates (ADCs) have been at the forefront in cancer therapy due to their target specificity. All the FDA approved ADCs are developed in lyophilized form to minimize instability associated with the linker that connects the cytotoxic drug and the antibody during shipping and storage. We present here solid-state hydrogen-deuterium exchange with mass spectrometric analysis (ssHDX-MS) as a tool to analyze protein structure and matrix interactions for formulations of an ADC with and without commonly used excipients. We compared results of the ssHDX-MS with accelerated stability results using size-exclusion chromatography and determined that the former technique was able to successfully identify the destabilizing effects of mannitol and polysorbate 80. In comparison, Fourier-transform infrared spectroscopy results were inconclusive. The agreement between ssHDX-MS and stressed stability studies supports the potential of ssHDX-MS as a method of predicting relative stability of different formulations.
Collapse
Affiliation(s)
- Eunbi Cho
- Department of Industrial and Physical Pharmacy, Purdue University, Robert E. Heine Pharmacy Building, 575 W Stadium Ave, West Lafayette, IN 47907, United States
| | | | | | - Gregory A Sacha
- Baxter BioPharma Solutions, Bloomington, IN 47403, United States
| | - Steven L Nail
- Baxter BioPharma Solutions, Bloomington, IN 47403, United States
| | - Elizabeth M Topp
- Department of Industrial and Physical Pharmacy, Purdue University, Robert E. Heine Pharmacy Building, 575 W Stadium Ave, West Lafayette, IN 47907, United States; National Institute for Bioprocessing Research and Training, Dublin 6, Ireland.
| |
Collapse
|
8
|
McMahon M, Williams H, Debie E, Fu M, Bujalski R, Qiu F, Wu Y, Li H, Wang J, Hoaglund-Hyzer C, Pulliam D. Utilization of risk-based predictive stability within regulatory submissions; industry’s experience. AAPS OPEN 2020. [DOI: 10.1186/s41120-020-00034-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
AbstractRisk-Based Predictive Stability (RBPS) tools, such as the Accelerated Stability Assessment Program (ASAP) and other models, are used routinely within pharmaceutical development to quickly assess stability characteristics, especially to understand mechanisms of degradation. These modeling tools provide stability insights within weeks that could take months or years to understand using long-term stability conditions only. Despite their usefulness, the knowledge gained through these tools are not as broadly used to support regulatory filing strategies. This paper aims to communicate how industry has used RBPS data to support regulatory submissions and discuss the regulatory feedback that was received.
Collapse
|
9
|
Williams HE, Bright J, Roddy E, Poulton A, Cosgrove SD, Turner F, Harrison P, Brookes A, MacDougall E, Abbott A, Gordon C. A comparison of drug substance predicted chemical stability with ICH compliant stability studies. Drug Dev Ind Pharm 2018; 45:379-386. [DOI: 10.1080/03639045.2018.1542707] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- H. E. Williams
- Pharmaceutical Technology and Development, AstraZeneca, Macclesfield, UK
| | - J. Bright
- Pharmaceutical Technology and Development, AstraZeneca, Macclesfield, UK
| | - E. Roddy
- Pharmaceutical Science, AstraZeneca, Macclesfield, UK
| | - A. Poulton
- Pharmaceutical Science, AstraZeneca, Macclesfield, UK
| | - S. D. Cosgrove
- Pharmaceutical Technology and Development, AstraZeneca, Macclesfield, UK
| | - F. Turner
- Pharmaceutical Technology and Development, AstraZeneca, Macclesfield, UK
| | - P. Harrison
- Pharmaceutical Technology and Development, AstraZeneca, Macclesfield, UK
| | - A. Brookes
- Pharmaceutical Technology and Development, AstraZeneca, Macclesfield, UK
| | - E. MacDougall
- Pharmaceutical Technology and Development, AstraZeneca, Macclesfield, UK
| | - A. Abbott
- Pharmaceutical Technology and Development, AstraZeneca, Macclesfield, UK
| | - C. Gordon
- Regulatory CMC, AstraZeneca, Macclesfield, UK
| |
Collapse
|
10
|
Jiang FC, Zhang HN, Wu D, Feng N, Zhang Z, Zhang JS, Feng J, Yang Y. Kinetic models for the effect of temperature on flavonoid production in liquid submerged fermentation byPhellinus baumii. Biotechnol Appl Biochem 2018; 65:739-747. [DOI: 10.1002/bab.1658] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Accepted: 03/16/2018] [Indexed: 11/06/2022]
Affiliation(s)
- Fu-Chun Jiang
- Institute of Edible Fungi; Shanghai Academy of Agricultural Sciences; Shanghai People's Republic of China
- Shanghai Ocean University; Shanghai People's Republic of China
| | - He-Nan Zhang
- Institute of Edible Fungi; Shanghai Academy of Agricultural Sciences; Shanghai People's Republic of China
- Key Laboratory of Edible Fungi Resources and Utilization (South); Ministry of Agriculture; Shanghai People's Republic of China
| | - Di Wu
- Institute of Edible Fungi; Shanghai Academy of Agricultural Sciences; Shanghai People's Republic of China
- Key Laboratory of Edible Fungi Resources and Utilization (South); Ministry of Agriculture; Shanghai People's Republic of China
| | - Na Feng
- Institute of Edible Fungi; Shanghai Academy of Agricultural Sciences; Shanghai People's Republic of China
- Key Laboratory of Edible Fungi Resources and Utilization (South); Ministry of Agriculture; Shanghai People's Republic of China
| | - Zhong Zhang
- Institute of Edible Fungi; Shanghai Academy of Agricultural Sciences; Shanghai People's Republic of China
- Key Laboratory of Edible Fungi Resources and Utilization (South); Ministry of Agriculture; Shanghai People's Republic of China
| | - Jing-Song Zhang
- Institute of Edible Fungi; Shanghai Academy of Agricultural Sciences; Shanghai People's Republic of China
- Key Laboratory of Edible Fungi Resources and Utilization (South); Ministry of Agriculture; Shanghai People's Republic of China
| | - Jie Feng
- Institute of Edible Fungi; Shanghai Academy of Agricultural Sciences; Shanghai People's Republic of China
- Key Laboratory of Edible Fungi Resources and Utilization (South); Ministry of Agriculture; Shanghai People's Republic of China
| | - Yan Yang
- Institute of Edible Fungi; Shanghai Academy of Agricultural Sciences; Shanghai People's Republic of China
- Key Laboratory of Edible Fungi Resources and Utilization (South); Ministry of Agriculture; Shanghai People's Republic of China
| |
Collapse
|
11
|
Patterson A, Ferreira AP, Banks E, Skeene K, Clarke G, Nicholson S, Rawlinson-Malone C. Modelling drug degradation in a spray dried polymer dispersion using a modified Arrhenius equation. Int J Pharm 2015; 478:348-360. [DOI: 10.1016/j.ijpharm.2014.11.063] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Revised: 11/26/2014] [Accepted: 11/27/2014] [Indexed: 10/24/2022]
|
12
|
do Nascimento TG, de Jesus Oliveira E, Basílio Júnior ID, de Araújo-Júnior JX, Macêdo RO. Short-term stability studies of ampicillin and cephalexin in aqueous solution and human plasma: Application of least squares method in Arrhenius equation. J Pharm Biomed Anal 2013; 73:59-64. [DOI: 10.1016/j.jpba.2012.04.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Revised: 04/06/2012] [Accepted: 04/09/2012] [Indexed: 10/28/2022]
|